Inequalities in pharmacologic treatment of spasticity in Sweden - health economic consequences of closing the treatment gap.
Annabelle ForsmarkLinda RosengrenPer ErtzgaardPublished in: Health economics review (2020)
There is a marked variation in pharmacologic treatment of adult spasticity in Sweden. Overall, the results indicate an underuse of treatment and need for harmonisation of clinical practice. Furthermore, the incremental cost for reaching treatment equity is likely to be offset by spasticity-associated cost-savings.